Like CD8+ T cells, Tregs also infiltrate the tumor stroma and a low CD8+ T cells to Tregs ratio is a poor indicator of disease outcome, overall survival and treatment outcomes in ovarian [92], breast [93] and bladder cancers [94]. Here, CD8A is linked to neoplasm.